PMID- 21744283
OWN - NLM
STAT- MEDLINE
DCOM- 20120315
LR  - 20221207
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
VI  - 21
IP  - 9
DP  - 2011 Sep
TI  - Safety and efficacy of Roux-en-Y gastric bypass to treat type 2 diabetes mellitus 
      in non-severely obese patients.
PG  - 1330-6
LID - 10.1007/s11695-011-0463-5 [doi]
AB  - The efficacy of Roux-en-Y gastric bypass (RYGB) to control type 2 diabetes 
      mellitus (T2DM) has been demonstrated in morbidly obese patients. Surgical 
      procedures primarily focused on T2DM control in patients with body mass index 
      (BMI) < 35 kg/m(2) have shown to effectively induce remission of T2DM. However, 
      only few reports have evaluated the safety and efficacy of RYGB in this group of 
      patients. The aim of this study is to assess the safety and efficacy of RYGB in 
      TD2M patients with BMI < 35 kg/m(2). All T2DM patients with BMI < 35 kg/m(2) and 
      at least 12 months of follow-up who underwent laparoscopic RYGB were included. 
      Safety of the procedure was evaluated according to mortality, need of 
      reoperation/conversion, and complication rates. Metabolic parameters were 
      evaluated at baseline and 6, 12, and 24 months after surgery. Thirty patients 
      were included. Seventeen (56.6%) were women. Age, BMI, and duration of diabetes 
      were 48 +/- 9 years, 33.7 +/- 1.2 kg/m(2), 4 +/- 2.9 years, respectively. No mortality 
      was observed. No conversion/reoperation was needed. Average length of stay was 
      3.2 +/- 0.9 days. Early and late postoperative complications were observed in five 
      (16.6%) and five (16.6%) patients, respectively. Twelve months after surgery, 
      remission was observed in 25 of 30 patients (83.3%). After 2 years, remission was 
      achieved in 13 of 20 patients (65%), and hemoglobin A1c decreased from 8.1 +/- 1.8% 
      to 5.9 +/- 1.1% and homeostasis model assessment of insulin resistance from 
      5.7 +/- 3.2 to 1.9 +/- 0.8 after 12 months. RYGB is a safe and effective procedure to 
      induce T2DM remission in otherwise not eligible patients for bariatric surgery. 
      Evidence from prospective studies is needed to validate this approach.
FAU - Boza, Camilo
AU  - Boza C
AD  - Department of Digestive Surgery, Faculty of Medicine, Pontificia Universidad 
      Catolica de Chile, Santiago, Chile. bozauc@med.puc.cl
FAU - Munoz, Rodrigo
AU  - Munoz R
FAU - Salinas, Jose
AU  - Salinas J
FAU - Gamboa, Cristian
AU  - Gamboa C
FAU - Klaassen, Julieta
AU  - Klaassen J
FAU - Escalona, Alex
AU  - Escalona A
FAU - Perez, Gustavo
AU  - Perez G
FAU - Ibanez, Luis
AU  - Ibanez L
FAU - Guzman, Sergio
AU  - Guzman S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
RN  - 0 (Biomarkers)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Diabetes Mellitus, Type 2/blood/complications/*surgery
MH  - Female
MH  - *Gastric Bypass/adverse effects
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypertension/complications
MH  - Laparoscopy
MH  - Length of Stay/statistics & numerical data
MH  - Lipid Metabolism Disorders/complications
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications/*surgery
MH  - Postoperative Complications/epidemiology
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Weight Loss
EDAT- 2011/07/12 06:00
MHDA- 2012/03/16 06:00
CRDT- 2011/07/12 06:00
PHST- 2011/07/12 06:00 [entrez]
PHST- 2011/07/12 06:00 [pubmed]
PHST- 2012/03/16 06:00 [medline]
AID - 10.1007/s11695-011-0463-5 [doi]
PST - ppublish
SO  - Obes Surg. 2011 Sep;21(9):1330-6. doi: 10.1007/s11695-011-0463-5.